We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE
George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’
George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’View Video
Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America
Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin AmericaView Video

Latest Share Chat

Biotech Growth's total return underperforms benchmark in tough market

Fri, 10th Nov 2023 14:22

(Alliance News) - Biotech Growth Trust PLC on Thursday said its net asset value decreased with a negative return in its latest half year, lamenting the "challenging backdrop" for its particular portfolio.

The London-based investor in global biotechnology companies said its NAV at September 30 was 817.9 pence per share, down from 852.6p at March 31.

Biotech Growth Trust shares were down 1.3% at 734.30p in London on Friday afternoon.

The company said it delivered a negative 4.1% total return for the six months that ended on September 30, underperforming the Nasdaq Biotechnology Index which delivered negative 3.0%. This was in sharp contrast to the first half of financial 2022, when Biotech Growth's total return was positive 9.6% while the benchmark posted a smaller positive 6.8% return.

Biotech Growth's cash balance at September 30 was GBP3.1 million, up from zero at the same time one year prior. It swung to a GBP13.7 million pretax loss for the half year, following a GBP37.0 million profit.

"The continuing difficult economic environment, rising cost of capital and associated investor caution all provided a challenging backdrop for a portfolio heavily weighted to small and mid sized biotechnology stocks," said Chair Roger Yates. "It is an environment which has persisted for some 18 months and lies at the heart of the recent poor performance of our company."

Going forward, Yates said the current macroeconomic climate is still "extremely challenging", but that "confidence can be found in the exciting range and pace of innovation in the biotech sector".

"The pace of innovation is accelerating and there is a robust pipeline of therapies based on a wide variety of scientific and technological developments," he continued. "The challenge of the forthcoming 'patent cliff' faced by larger biopharmaceutical companies is an opportunity for the emerging biotech companies in which your company is invested and we expect to see a further increase in merger and acquisition activity."

By Emma Curzon, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

Related Shares

More News
15 Jun 2023 11:56

Biotech Growth Trust net assets drop after "another difficult year"

(Alliance News) - Biotech Growth Trust on Thursday said its net asset value per share declined during financial 2023 and produced a negative return, w...

15 Jun 2023 09:40

SMALL-CAP WINNERS & LOSERS: Biotech Growth underperforms benchmark

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Thursday.

16 Nov 2022 14:54

EARNINGS SUMMARY: Biotech Growth, Dunedin Enterprise net assets grow

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Wednesday and not separately reported by Alliance News...

12 Jul 2022 15:39

UK shareholder meetings calendar - next 7 days

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.